EN
The goal of the research was to evaluate the usefulness of the preparate Baypamun in the treatment of clinical upper respiratory tract infections in dogs. The studies were performed on 60 sick dogs with signs of upper respiratory tract inflamation. All of the sick dogs received Baypamun or a placebo separately or in combination with Baytril. There was no positive response to the administration of the placebo. In the group which received only Baypamun a systematic disappearance of signs until their complete remission was observed. The results of the application of combinations of placebo+Baytril and Baypamun+Baytril were similar. In both groups the therapy used led to complete healing. However, the signs of sickness in the group treated with the combination of Baypamun and Baytril disappeared quicker than those in the group treated with Baytril and the placebo. The use of Baypamun did not cause any side effects. Baypamun can confidently be used as a product for the therapy of weak infections or as supportive treatment of sub-acute upper respiratory tract infections in dogs.